Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of DNL343 in amyotrophic lateral sclerosis
NL-OMON56265Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNL343 in amyotrophic lateral sclerosis (ALS), sponsored by Denali Therapeutics Inc. Started Aug 2021; status: completed.
02
Drugs
DNL343
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON56265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56265.